Search
Polatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigational[L6658] The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl
Products: POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 140MG, POLIVY POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 30MGIsavuconazole
go.drugbank.com/drugs/DB11633ApprovedInvestigationalhas a potential for nephrotoxicity [A32029]. … Invasive fungal infections pose significant clinical challenges for patients, especially those who are immunocompromised.
Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic UseProducts: CRESEMBA (POWDER FOR SOLUTION FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 MG/VIAL)Tolfenamic acid
go.drugbank.com/drugs/DB09216ApprovedBy the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291] … It is used in the UK as a treatment for migraine under the name of Clotam.[L1292] In the US, it presents a Status class I by the FDA.
Products: TOLFEDINE 4% W/V SOLUTION FOR INJECTION FOR DOGS AND CATS, Tolfine Solution for Injection 4.0% W/VNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigational[L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability.
Products: OPDIVO CONCENTRATE FOR SOLUTION FOR INFUSION 10 MG/ML, NIVOLUMAB BMS CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/MLPralatrexate
go.drugbank.com/drugs/DB06813ApprovedInvestigationalPralatrexate is an antifolate for the treatment of relapsed or refractory peripheral T-cell lymphoma [L37674]. … Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts.
Products: SOLUTION FOR INFUSION 20MG/ML, Folotyn 20mg/ml Solution for InfusionPeginterferon alfa-2b
go.drugbank.com/drugs/DB00022ApprovedInvestigational-2b for the treatment of Hepatitis C [A19593]. … When combined together, Peginterferon alfa-2b and [Ribavirin] have been shown to achieve a SVR between 41% for genotype 1 and 75% for genotypes 2-6 after 48 weeks of treatment.
Categories: Treatments for Hepatitis CProducts: PEG-INTRON CLEARCLICK FOR INJECTION 80 mcg/0.5 ml, PEG-INTRON CLEARCLICK FOR INJECTION 100 mcg/0.5 mlIbandronate
go.drugbank.com/drugs/DB00710ApprovedInvestigational[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805]
Categories: Drugs for Treatment of Bone DiseasesProducts: BONVIVA 3MG/3ML FER, IBANDRONSAEURE AL 3 MG FERCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10584ApprovedInvestigationalMixtures: , Suspension for Injection, ADACEL SUSPENSION FOR INJECTIONCategories: Antiinfectives for Systemic UseEculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigational[L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria
Products: Soliris Concentrate for Solution for Infusion 300mg/vial, Soliris 10mg/ml Concentrate for Solution for InfusionTuroctocog alfa
go.drugbank.com/drugs/DB09109ApprovedTuroctocog alfa is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally
Products: NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIAL, NOVOEIGHT POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250IU/VIAL